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to be mediated by intimal thickening and
media attenuation in proximal vessels,
along with abnormal smooth muscle cell
turnover and neovascularization in distal
vessels.18

Moyamoya Syndrome

INTRODUCTION
Moyamoya disease is a rare progressive cerebrovascular disease characterized by
bilateral stenosis of vasculature of the Circle of Willis, specifically the distal internal
carotid arteries, that leads to extensive collateral circulation. These dilated collateral
vessels are described as having a hazy “puff of smoke” appearance on angiography.
“Moyamoya” is the Japanese word for this characteristic appearance. The disease was
originally described in Japan in 1957 1 and introduced to the English literature in 1969. 2
The disease is most known for its distribution in Asian populations, but recently there has
been more research and attention given to moyamoya in Europe and North American
Moyamoya disease presents clinically due to the ischemic and hemorrhagic complications of abnormal cerebral vascularity. 3,4

Epidemiology
Moyamoya disease was originally described in Japanese populations but is present in a
variety of ethnicities.3,5,6 In Japan, the incidence per 100,000 patient years is between
0.35 to 0.943 with a male: female ratio of 1:1.87. In the US, incidence ranged from 0.05
to 0.17 per 100,000 patient years with a similar gender distribution. 3,6 Other population
studies have not been as robust but European studies show moyamoya statistics that
are more similar to American findings than those of Asian moyamoya findings.4 There is
a bimodal distribution of incidence: in early childhood and adulthood, but the doublepeaked incidence is less dramatic in the US and Europe.4,8 Children typically present with
the ischemic symptoms and adults can present with either ischemic or hemorrhagic
type, with the ischemic type predominating.5,9 Overall, the hemorrhagic type is more
common in Asia than the U.S.9 The incidence has been increasing with time, which may
be due to increased awareness.5

Etiology
The etiology of moyamoya disease is largely unknown. However, there are genetic
susceptibilities and biochemical correlates that warrant further research. This importance is highlighted in the 10-15% of moyamoya disease cases that are familial.10 The
proposed mechanism of inheritance is autosomal dominant with incomplete penetrance
but it is likely there are polygenic interactions as well.11 Currently, screening is not recommended for moyamoya disease.
The first gene associated with moyamoya disease was RNF213 on chromosome 17.12
Animal models show that knockout of this gene causes arterial abnormalities with wall
malformation and abnormal angiogenesis.13 Another study showed that different mutations of this ring finger protein are associated with different clinical presentations of
moyamoya: R4810K mutation with the ischemic form and A4399T mutation with the
hemorrhagic form.14
There is evidence of a dysregulation of a variety of extracellular matrix proteins in
moyamoya, including basic fibroblast growth factor,15 transforming growth factor beta116, and vascular endothelial growth factor.17 A tentative pathologic process is believed
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Moyamoya disease is characterized
by an idiopathic abnormal vasculature
adjacent to the circle of Willis with extensive compensatory collateral vessels.
Moyamoya syndrome is a separate entity,
associated with another disease that
causes a similar angiographic appearance. 19 The most common examples
of diseases that can cause moyamoya
syndrome are sickle-cell disease, neurofibromatosis type I, cranial irradiation, and
Down syndrome. Even without these risk
factors, a unilateral presentation is also
considered to be moyamoya syndrome
since moyamoya disease is defined as
a bilateral disease. 20 The distinction
between these two entities is critical for
an appropriate clinical approach.

CLINICAL PRESENTATION
Moyamoya disease can be asymptomatic in early stages, or present with a
range of symptoms associated with
the abnormal vasculature including
headaches, seizures, hemiparesis, and
sensory impairment. The two major
types of manifestations are ischemic and
hemorrhagic. Ischemic symptoms are
associated with insufficient perfusion and
infarcts are typically small and located in
the basal ganglia. 21 Hemorrhages can
occur due to the poorly formed collateral arterial supply and result in a worse
prognosis.5 Roughly half of patients have
a single symptomatic episode and half
have multiple recurrences of ischemic
events. 23 Recurrences in the pediatric
population are associated with stress,
hyperventilation, dehydration, and crying,
which are important factors to recognize
and explain to the patient’s family for
prevention measures.19
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DIAGNOSIS AND IMAGING
It is important that Moyamoya is considered in patients with stroke-like symptoms
due to its unique clinical approach. This is
especially important to keep in mind with
pediatric patients since 6% of pediatric
strokes are due to moyamoya disease.5,9,22
Due to the symptoms at presentation,
the initial imaging study of these patients
is typically computed tomography (CT).
CT can identify ischemic lesions from
the basal ganglia (earlier stages) to the
cortex (later stages) but can be normal
if the lesions are small. 24 Commonly, the
diagnosis of moyamoya disease requires
multiple imaging modalities. Brain MRI is
more sensitive for these smaller lesions
and can also identify punctuate flow
voids in the basal ganglia which is highly
suggestive of moyamoya disease.19
The gold standard for diagnosis is conventional cerebral angiography. Transcranial
Doppler studies can also be useful to
noninvasively detect stenotic vessels via
an increased flow rate and track changes
in this flow over time. 25

THERAPEUTIC OPTIONS
The mainstay of treatment for patients of
all age groups presenting with Moyamoya
continues to be neurosurgical intervention. Surgery is the only means by which
the morbidity and mortality of the disease
can be dramatically reduced. There is
no agreed upon medical regimen, and
the only medical options available treat
the complications of the disease. For
example; aspirin may be given to inhibit
the formation of microthromboemboli
that could cause ischemia (surgical
patients are given this routinely); calcium
channel blockers have been reported to
improve intractable headaches; and fluids
are given to avoid hypoperfusion. 26
The disease is inevitably progressive, 27
and the single most important prognostic
indicator is neurologic status at the time
of treatment.26 Surgery is considered first
line as a preventative measure against
stroke and neurologic decline, 27 serious
complications for the relatively young
patient population affected by moyamoya.
If there are contraindications to surgery,
such as a recent stroke or infection, or
if the patient has adequate collateral
circulation, medical management may
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be chosen over surgery. 27,28 Symptomatic
patients treated medically show much
higher rates of recurrent stroke than
surgical patients. 29

Revascularization
Surgical revascularization techniques
aim to increase cerebral blood flow to
affected territories, and to indirectly shrink
the aberrant collaterals that have formed
as a result of ICA stenosis. A variety of
direct, indirect and combined surgical
techniques have been employed, which
can decrease the frequency of ischemic
and hemorrhagic events that occur and
therefore improve functional outcomes.30
For the purpose of discussion, direct and
indirect approaches can be separated
into two distinct categories. In practice,
however, the combined approach more
effectively promotes long-term revascularization, and has not been proven
to increase complication rates over one
technique alone. 23,27

Direct Bypass
Direct revascularization involves the
anastomosis of the superficial temporal
artery with the middle cerebral artery,
distal to the stenotic region. 30 This allows
for an immediate increase in blood flow
to previously hypoperfused territories
of the brain. This method has better
revascularization outcomes than indirect methods alone. 23 One concerning
complication of this method, however,
if there is inadequate blood pressure
control, is postoperative hyperperfusion,
which can lead to seizures. 27 Also, this
bypass is not always feasible in children
as their vessels are of a smaller diameter,27
so indirect methods are often relied upon
in the pediatric population.31

Indirect Revascularization
Indirect revascularization describes a
number of surgeries with the unifying
theme of applying richly vascular tissue on
top of the hypoperfused region in order
to promote angiogenesis. 27 Ultimately,
the transposed vessel anastomoses
with the existing vasculature, which can
significantly improve flow through the
previously undersupplied vessels. Potential issues with this technique include
the time delay of weeks to months
after surgery before the target tissue is
perfused, and the potential for mass effect,

as you are introducing relatively large
sections of tissue into critically eloquent
areas of cerebral cortex. 32 Tissue can be
taken from, for example, the omentum
(omental transplantation) or the temporalis muscle (encephalomyosynangiosis),
but the three most commonly utilized
indirect techniques in North America are
encephaloduroarteriosynangiosis (EDAS),
encephaloduroarteriomyosynangiosis
(EDAMS), and multiple burr hole placement (MBH).30
The EDAS procedure requires suturing the
STA and a tissue cuff to the dura overlying
the target area. Burr holes are used to
facilitate the craniotomy. Many variations
exist, but one popular technique, pial
synangiosis, involves attaching the STA
and tissue cuff directly to the pia. EDAMS
is a more involved procedure that involves
utilization of the deep temporal, superficial temporal, and middle meningeal
arteries.32 MBH is the least invasive technique, more commonly used in children
than adults, and requires the placement
of a number of burr holes through small
cuts in the periosteum. This allows for
targeting of specific tissue regions and
promotes angiogenesis in those areas. 32

PROGNOSIS
Moyamoya, as mentioned above, is
inherently progressive. 25,26 The natural
history of the disease cannot be
changed by intervention, but it can be
delayed significantly, and the functional
status of the patient kept remarkably
intact. 30 Outcomes are best predicted
by neurologic status at treatment, and
presentation with a stroke (hemorrhagic
more than ischemic) was found to be the
greatest predictor of mortality during
hospital stay for treatment.5,26,27 In North
America, where presentation is primarily
ischemic regardless of age group, childhood diagnosis is considered to have a
worse prognosis.30 When left untreated,
even asymptomatic patients will progress
to the point of potentially devastating
recurrent strokes, but with early diagnosis
and surgical intervention individuals can
live for many years with a dramatically
lower risk of the morbidities associated
with moyamoya disease. 33,34
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